Erratum: Department of Error (The Lancet (2016) 387(10036) (2382) (S0140673616001641) (10.1016/S0140-6736(16)00164-1));Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma

The Lancet

Volumn 387, Issue 10036, 2016, Pages 2360-2361

  Jabbour, Elias ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; INOTUZUMAB OZOGAMICIN; OBINUTUZUMAB; OFATUMUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NOTE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BURKITT LYMPHOMA; FEMALE; HUMANS; MALE; RITUXIMAB;

EID: 84964343843     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30740-1     Document Type: Erratum

References (12)

1. 1 Jabbour, E, Kantarjian, H, Ravandi, F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16 (2015), 1547–1555.
2. 2 Jabbour, E, O'Brien, S, Ravandi, F, Kantarjian, H, Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125 (2015), 4010–4016.
3. 3 Coiffier, B, Lepage, E, Briere, J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 235–242.
4. 4 Hallek, M, Fischer, K, Fingerle-Rowson, G, et al., for the German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 (2010), 1164–1174.
5. 5 Hoelzer, D, Walewski, J, Dçhner, H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124 (2014), 3870–3879.
6. 6 Ribrag, V, Koscielny, S, Bosq, J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet, 2016 published online April 11. http://dx.doi.org/10.1016/S0140-6736(15)01317-3.
7. 7 Maury S, Chevret S, Thomas X, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized GRAALL-R 2005 study. American Society of Haematology 57th Annual Meeting and Explosition; Orlando, FL, USA; Dec 5–8, 2015. Abstract 1.
8. 8 Jabbour E, O'Brien S, Sasaki K, et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with acute lymphoblastic leukemia (ALL). American Society of Haematology 57th Annual Meeting and Explosition; Orlando, FL, USA; Dec 5–8, 2015. Abstract 83.
9. 9 Topp, MS, Goekbuget, N, Stein, AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16 (2015), 57–66.
10. 10 Gçkbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). American Society of Haematology 57th Annual Meeting and Explosition; Orlando, FL, USA; Dec 5–8, 2015. Abstract 680.
11. 11 Kantarjian, H, Thomas, D, Jorgensen, J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119 (2013), 2728–2736.
12. 12 DeAngel DJ, Stelljes M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 in patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study. 20th Congress of the European Hematology Association; Vienna, Austria; June 11–14, 2015. Abstract LB2073.